Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP, Chief Legal Officer | August 05, 2021 | August 09, 2021 |
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | August 01, 2026 | August 03, 2026 |
| PepGen Inc.PEPG · Entity 6253 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 05, 2021 · Filed August 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,132 |
Ending reported balance
After 2021-08-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-08-05 · Exercise / conversion · Acquired 7,876 · Balance 13,008 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Row 2 · 2021-08-05 · Exercise / conversion · Acquired 2,124 · Balance 15,132 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Row 3 · 2021-08-05 · Sale · Disposed 10,000 · Balance 5,132 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. |
| Performance Stock Option 2015 (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.95 · Expires 2025-12-18 | Direct | 11,876 |
Reported balance
After 2021-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-05 · Exercise / conversion · Disposed 2,124 · Balance 11,876 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.95 · Expires 2025-12-18 | Direct | 1,124 |
Reported balance
After 2021-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-05 · Exercise / conversion · Disposed 7,876 · Balance 1,124 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. F3: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 434 |
Reported balance
Holding disclosure · report date 2021-08-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 434 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F3: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Kalaris Therapeutics, Inc.
Report date August 01, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2036-07-31 | Direct | 18,000 |
Reported balance
After 2026-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-01 · Grant · Acquired 18,000 · Balance 18,000 F1: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.
PepGen Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2036-06-17 | Direct | 34,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 34,000 · Balance 34,000 F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Imago BioSciences, Inc.
Report date January 11, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.76 · Expires 2031-11-16 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-11 · Disposition to issuer · Disposed 23,809 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.65 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-11 · Disposition to issuer · Disposed 11,904 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2019 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000044 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date. Read SEC document |
| April 09, 2019 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 41 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000044 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 375 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000031 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 12,500 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 18, 2018 Filed Jun 7, 2019 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000044 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 334 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:59 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000076 · edgardoc.xml · derivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:59 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000076 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000059 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 605 | $90.95 | $55,024.75 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,258 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 1,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,863 F1 · kind: On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2014 (right to buy) · Derivative | 1,984 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,958 Underlying: Common Stock · 1,984 shares Expires 2024-12-17 F3 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| July 10, 2018 Filed Aug 14, 2018 22:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000050 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 320 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000035 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,626 Underlying: Common Stock · 1,563 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,563 | $105.04 | $164,177.52 |
DisclosureSEC source: 0001735276-18-000035 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F2 · price: Sale prices ranged from $104.73 to $105.35 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,563 | $42.22 | $65,989.86 |
DisclosureSEC source: 0001735276-18-000035 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| April 16, 2018 Filed Jun 22, 2018 20:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000035 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 288 F3 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F3 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F3 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,562 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · derivative · entry 8 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,189 Underlying: Common Stock · 1,562 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F7 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 300 | $152.79 | $45,837.00 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 6 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F5 · price: Sale prices ranged from $152.48 to $153.30 Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 200 | $151.48 | $30,296.00 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 5 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F4 · price: Sale prices ranged from $151.46 to $151.50 Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 500 | $149.97 | $74,985.00 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F3 · price: Sale prices ranged from $149.60 to $150.54 Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 462 | $147.79 | $68,278.98 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F2 · price: Sale prices ranged from $147.40 to $148.05 Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 100 | $146.36 | $14,636.00 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,962 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 22:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,562 | $42.22 | $65,947.64 |
DisclosureSEC source: 0001553878-18-000029 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · derivative · entry 7 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,000 | $150.00 | $1,500,000.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $77.40 | $774,000.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · derivative · entry 6 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,000 | $140.00 | $1,400,000.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:40 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $77.40 | $774,000.00 |
DisclosureSEC source: 0001553878-18-000023 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:48 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001553878-18-000011 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2028-02-28 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 13,750 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001325812-18-000001 · primary_doc.xml · derivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 3,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionCommon Stock | 3,000 | $77.40 | $232,200.00 |
DisclosureSEC source: 0001325812-18-000001 · primary_doc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 6,249 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · derivative · entry 7 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,751 Underlying: Common Stock · 6,249 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F7 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | GrantPerformance Based Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · derivative · entry 6 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F6 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | SaleCommon Stock | 300 | $122.53 | $36,759.99 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F4 · price: Sale prices ranged from $122.51 to $122.58. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | SaleCommon Stock | 1,900 | $121.67 | $231,181.93 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F3 · price: Sale prices ranged from $121.49 to $122.39. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | SaleCommon Stock | 4,049 | $120.88 | $489,456.48 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F2 · price: Sale prices ranged from $120.45 to $121.40. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionCommon Stock | 6,249 | $42.22 | $263,832.78 |
DisclosureSEC source: 0001325812-17-000038 · primary_doc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · derivative · entry 8 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 30,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F8 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,199 | $137.29 | $851,060.71 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 6 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F6 · price: Sale prices ranged from $137.04 to $137.73. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,700 | $136.50 | $1,324,050.00 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 5 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,699 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F5 · price: Sale prices ranged from $136.00 to $136.95. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,500 | $135.56 | $1,016,700.00 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,399 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F4 · price: Sale prices ranged from $134.99 to $135.93. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,801 | $134.59 | $511,576.59 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,899 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F3 · price: Sale prices ranged from $133.95 to $134.92. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,800 | $133.37 | $373,436.00 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. F2 · price: Sale prices ranged from $132.90 to $133.74. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 22:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 30,000 | $77.40 | $2,322,000.00 |
DisclosureSEC source: 0001553878-17-000070 · primary_doc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000064 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2014 (right to buy) · Derivative | 1,987 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000043 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,974 Underlying: Common Stock · 1,987 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| May 30, 2017 Filed May 31, 2017 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | PurchaseCommon Stock | 11,500 | $65.35 | $751,502.00 |
DisclosureSEC source: 0001553878-17-000015 · primary_doc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:19 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-16-000109 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 F1 · shares: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.